戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t potency for inhibition of human cytochrome P450 (3A4).
2 n drug molecules to metabolism by cytochrome P450 3A4.
3 erivative everolimus (SDZ-RAD) by cytochrome P450 3A4.
4  line engineered to express human cytochrome P450 3A4.
5 nhibitor, was investigated using recombinant P450 3A4.
6 t the entire molecule (M(r) 521) fits within P450 3A4.
7 able of conferring the P450 3A5 phenotype on P450 3A4.
8 substrate recognition site model of Gotoh to P450 3A4.
9 terpreted using a three-dimensional model of P450 3A4.
10 of several drugs that are largely cleared by P450 3A4.
11 activity of a key enzyme of drug metabolism, P450 3A4.
12 ocriptine (one bromine atom) with cytochrome P450 3A4.
13 sA, NC1153 was not metabolized by cytochrome P450 3A4.
14 syltransferase (UGT) isoforms and cytochrome P450 3A4.
15           None of the P450 enzymes examined (P450s 3A4, 1A2, 2E1, 2A6, 2D6, and 2C9) appeared to be i
16                                  Cytochromes P450 3A4, 2D6, and 2C9 metabolize a large fraction of dr
17  the functional activity of human cytochrome P450s 3A4, 2E1, 2B6, 2C9, 2C19, and 2D6 was also examine
18 P450 3A4 and not the 6alpha, indicating that P450 3A4 abstracts hydrogen and rebounds oxygen only at
19 inactivated P450 3A4 pertain to two distinct P450 3A4 active site domains.
20                         Limited successes in P450 3A4 active-site structure studies have been achieve
21 less, and can be used to confirm and measure P450 3A4 activity and can also be used as a guide for de
22                                   Cytochrome P450 3A4 activity was estimated using the carbon-14 [14C
23 ted with a significant decline in cytochrome P450 3A4 activity, which is predictive of clinically imp
24 atic microsomal metabolism of 1- and 4-NP to P450 3A4, although a minor role for P450 1A2 cannot be r
25  major drug-metabolizing enzymes (cytochrome P450 3A4 and 2D6 [CYP3A4 and CYP2D6]) were also measured
26 ceprevir is a strong inhibitor of cytochrome P450 3A4 and 3A5 (CYP3A4/5).
27                                  Cytochromes P450 3A4 and 3A5, the dominant drug-metabolizing enzymes
28 by incubation with cholesterol; the level of P450 3A4 and cell viability were not altered under the c
29 baculovirus and bacterial membranes in which P450 3A4 and NADPH-P450 reductase were coexpressed; the
30       Only the 6beta-hydrogen was removed by P450 3A4 and not the 6alpha, indicating that P450 3A4 ab
31 ions and the presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaba
32 those treated with >/= 1 combined cytochrome P450 3A4 and P-glycoprotein inhibitors.
33 i) values for blocking the binding to ferric P450 3A4 and the oxidation of several substrates may be
34 tes was catalyzed by P450 3A4 (for 5-MeC) or P450s 3A4 and 1A2 (for 6-MeC).
35 nderstand the structural differences between P450s 3A4 and 3A5, the structure of 3A5 complexed with r
36 )-position is selectively catalyzed by human P450s 3A4 and 3A5, with the latter being more efficient,
37 9-hydroxylation reactions were attributed to P450 3A4, and 18- and 19-hydroxydihydrotestosterone were
38 erol is both a substrate and an inhibitor of P450 3A4, and a model is presented to explain the kineti
39 s an effective photoaffinity ligand of human P450 3A4, and mass spectrometry data demonstrating the e
40                                              P450 3A4 apparently prefers AFB1 3alpha-hydroxylation, w
41 d, 14C-heme labeled, recombinant human liver P450 3A4 as the target of CuOOH-mediated inactivation, a
42  norbuprenorphine formation was detected for P450s 3A4, as previously described, but also for 3A5, 3A
43 ), rat liver (RLM) and bicistronic human-cyt P450 3A4 (bicis.-3A4) microsomes as enzyme sources.
44                                          The P450 3A4 binding process is more complex than a two-stat
45               YPFP-NH(2) was not oxidized by P450 3A4 but blocked binding of the substrates testoster
46 of a saturated 8,9-bond, was not oxidized by P450 3A4 but could inhibit AFB1 oxidation.
47  Mechanism-based inactivation of human liver P450 3A4 by L-754,394, a Merck compound synthesized as a
48 In contrast, alpha-naphthoflavone stimulated P450 3A4 by selectively binding and activating an otherw
49 ors, inhibitors, or substrates of cytochrome P450 3A4 can be expected.
50 homotropic and heterotropic cooperativity in P450 3A4-catalyzed oxidations is not well understood, an
51                    Cholesterol inhibited the P450 3A4-catalyzed oxidations of nifedipine and quinidin
52 imethyl-2-aminofluorene N-oxygenation, human P450 3A4-catalyzed quinidine N-oxygenation, rat P450 2B1
53                                              P450 3A4 catalyzes the metabolic clearance of a large nu
54 d activates gene transcription of cytochrome p450-3A4, causing significant botanical-drug interaction
55 ctra indicated a K(d) value of 8 muM for the P450 3A4-cholesterol complex.
56                                   Cytochrome P450 3A4 (CYP3A4) activity and docetaxel pharmacokinetic
57  and topiramate, enhances hepatic cytochrome P450 3A4 (CYP3A4) activity, and can decrease serum conce
58 onally homogeneous 1:1 complex of cytochrome P450 3A4 (CYP3A4) and cytochrome P450 reductase solubili
59 cells and increased expression of cytochrome P450 3A4 (CYP3A4) and multidrug resistance 1 (MDR1).
60 conformational landscape of human cytochrome P450 3A4 (CYP3A4) by electron paramagnetic resonance and
61 as a mechanism-based inhibitor of cytochrome P450 3A4 (CYP3A4) by forming adducts with the apoprotein
62             This study employed a cytochrome P450 3A4 (CYP3A4) crystal structure (Protein Data Bank e
63                                   Cytochrome P450 3A4 (CYP3A4) displays non-Michaelis-Menten kinetics
64 e hepatocyte-like cells exhibited cytochrome P450 3A4 (CYP3A4) enzyme activity, secreted urea, uptake
65  cancer drug, in interaction with cytochrome P450 3A4 (CYP3A4) enzyme and multiwalled carbon nanotube
66 N can significantly down-regulate cytochrome P450 3A4 (CYP3A4) expression in human primary hepatocyte
67    Allosteric mechanisms in human cytochrome P450 3A4 (CYP3A4) in oligomers in solution or monomeric
68 tituent alleviated time-dependent cytochrome P450 3A4 (CYP3A4) inhibition.
69                Utilization of the cytochrome P450 3A4 (CYP3A4) inhibitor ritonavir as a pharmacoenhan
70                                   Cytochrome P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, c
71                             Human cytochrome P450 3A4 (CYP3A4) is a key xenobiotic-metabolizing enzym
72        The membrane-bound protein cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme.
73                                   Cytochrome P450 3A4 (CYP3A4) is a major enzymatic determinant of dr
74                             Human cytochrome P450 3A4 (CYP3A4) is a major hepatic and intestinal enzy
75                                   Cytochrome P450 3A4 (CYP3A4) is the dominant P450 enzyme involved i
76                                   Cytochrome P450 3A4 (CYP3A4) is the dominant xenobiotic metabolizin
77                                   Cytochrome P450 3A4 (CYP3A4) is the most abundant membrane-associat
78      The drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is thought to be involved in the metab
79                                   Cytochrome P450 3A4 (CYP3A4) metabolizes more drug molecules than a
80                                   Cytochrome P450 3A4 (CYP3A4) metabolizes more than 50% of prescribe
81                                   Cytochrome P450 3A4 (CYP3A4) plays a critical role in the metabolis
82  Statins primarily metabolized by cytochrome P450 3A4 (CYP3A4) reportedly reduce clopidogrel's metabo
83 homotropic cooperativity in human cytochrome P450 3A4 (CYP3A4) we studied the interactions of the enz
84 or human drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) were explored with fluorescence resona
85              One of such enzymes, cytochrome P450 3A4 (CYP3A4), plays critical roles in drug metaboli
86 t conformational heterogeneity of cytochrome P450 3A4 (CYP3A4), the kinetics of dithionite-dependent
87  to determine hepatic activity of cytochrome P450 3A4 (CYP3A4), the main docetaxel-metabolizing enzym
88                     Inhibition of cytochrome P450 3A4 (CYP3A4), the major drug metabolizing enzyme, b
89                         Monomeric cytochrome P450 3A4 (CYP3A4), the most prevalent cytochrome P450 in
90 ory region of the PXR target gene cytochrome P450 3A4 (CYP3A4), with a concomitant methylation of arg
91 g binding to human membrane-bound cytochrome P450 3A4 (CYP3A4).
92 olchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketocona
93 l blockers are metabolized by the cytochrome P450 3A4 (CYP3A4; EC 1.14.13.97) enzyme.
94 ents having a variant genotype of cytochrome P450 3A4 displayed higher blood concentrations of parent
95 s showed that ritonavir inhibited cytochrome P450 3A4 enzyme (CYP3A4) in liver microsomes.
96 osterone and demonstrates the sensitivity of P450 3A4, even with its large active site, to small chan
97                                              P450 3A4 exhibits a relatively large substrate-binding c
98  inhibitors and substrates of the cytochrome P450 3A4 family.
99 e hydroxymethyl metabolites was catalyzed by P450 3A4 (for 5-MeC) or P450s 3A4 and 1A2 (for 6-MeC).
100        Of several human P450s examined, only P450 3A4 formed this product.
101                             Human cytochrome P450 3A4 forms a series of minor testosterone hydroxylat
102                     PXR activates cytochrome P450 3A4 gene expression upon binding to rifampicin (Rif
103 being only a minor reaction, indicating that P450 3A4 has considerable control over the course of ste
104 and used to probe the catalytic mechanism of P450 3A4: (i) 2,2,4,6,6-(2)H(5); (ii) 6,6-(2)H(2); (iii)
105 sting of their potential to label cytochrome P450 3A4 in a light-dependent fashion.
106  residues at positions 364-377 of cytochrome P450 3A4 in determining steroid hydroxylation or stimula
107 c efficiencies were similar for P450 2D6 and P450 3A4 in the presence of cytochrome b(5) with (R)-ret
108      Midazolam appears to be able to bind to P450 3A4 in two modes, one corresponding to the testoste
109 g, HIC) but showed time-dependent cytochrome P450 3A4 inhibition, possibly related to morpholine ring
110 lavone allowed analysis of an initial ligand-P450 3A4 interaction that does not cause a perturbation
111                                   Cytochrome P450 3A4 is a drug-metabolizing enzyme of extraordinaril
112                                         Thus P450 3A4 is an enzyme with regioselective flexibility bu
113                                   Cytochrome P450 3A4 is an important mediator of drug catabolism tha
114                                   Cytochrome P450 3A4 is generally considered to be the most importan
115 nding of interaction of drug inhibitors with P450 3A4 is important in predicting clinical drug-drug i
116                             Cytochrome P450 (P450) 3A4 is an extensively studied human enzyme involve
117                             Cytochrome P450 (P450) 3A4 is the most abundant human P450 and oxidizes a
118                             Cytochrome P450 (P450) 3A4 is the most abundant human P450 enzyme and has
119 on by phenytoin and rifampicin of cytochrome P450 3A4 isoform that converts monocrotaline to toxic in
120  human liver microsomes, did not inhibit the P450 3A4 isozyme, and had low protein binding (18.22% fo
121  on drugs that are susceptible to cytochrome P450 3A4-mediated hydrogen radical abstraction followed
122  molecule's ability to competitively inhibit P450 3A4-mediated oxidative metabolism of midazolam with
123                                   Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazep
124                                            A P450 3A4 model based on these peptide studies contains a
125 e-depleted C98S/C239S/C377S/C468A cytochrome P450 3A4 mutant designated CYP3A4(C58,C64) allowed site-
126                                Moreover, the P450 3A4 mutant N206S most closely mimicked P450 3A5, no
127                                       Of the P450 3A4 mutants examined, P107S, F108L, N206S, L210F, V
128                   In addition, some of these P450 3A4 mutations that affected AFB1 regioselectivity h
129 same patterns were seen with AFB1 in a fused P450 3A4-NADPH-P450 reductase protein.
130 roughput assay for measuring the activity of P450 3A4, one of the key enzymes involved in drug metabo
131 ptidase-C digestion of the CuOOH-inactivated P450 3A4 pertain to two distinct P450 3A4 active site do
132 ms containing purified recombinant bacterial P450 3A4, positive cooperativity was seen in oxidations
133 etric binding of the inactivating species to P450 3A4 precluded the direct identification of a covale
134 drug-drug interactions due to its cytochrome P450 3A4 profile.
135  high (D)k value was also seen with a slower P450 3A4 reaction, the O-dealkylation of 7-benzyloxyquin
136                                              P450 3A4 reduction was examined in liver microsomes, a r
137 utations resulted in a significant switch of P450 3A4 regioselectivity toward that of P450 3A5.
138                             The structure of P450 3A4 should facilitate a better understanding of the
139                                         Only P450 3A4 showed substantial catalytic activity for methy
140 d to weaker binding of YPFP-NH(2) to ferrous P450 3A4 than to the ferric form.
141 on amino acid residues 210-216 of cytochrome P450 3A4, the major drug-metabolizing enzyme of human li
142 ly regulates the transcription of cytochrome P450 3A4, the major human drug-metabolizing enzyme.
143 ase inhibitor and an inhibitor of cytochrome P450 3A4, the major human hepatic drug-metabolizing enzy
144 irected mutagenesis and computer modeling of P450 3A4, the most likely location of effector binding i
145                             Cytochrome P450 (P450) 3A4, the major catalyst involved in human drug oxi
146 is a prototypic reaction of cytochrome P450 (P450) 3A4, the major human P450.
147             If cholesterol is a substrate of P450 3A4, then it follows that it should also be an inhi
148 ) also argues that room should be present in P450 3A4 to bind more than one smaller ligand in the "te
149                             The structure of P450 3A4 was determined by x-ray crystallography to 2.05
150          L-754,394 that had been adducted to P450 3A4 was hydrolyzed under the conditions used for SD
151                                Specifically, P450 3A4 was responsible for the formation of 3-hydroxy-
152 r products formed during the inactivation of P450 3A4 were the monohydroxylated and the dihydrodiol m
153 d U-46619, induced spectral changes in human P450 3A4 with K(s) values of 240 +/- 20 and 130 +/- 10 m
154                             The finding that P450 3A4 with one altered residue, Leu210 --> Ala, can h
155                          The interactions of P450 3A4 with several structurally diverse inhibitors we
156 tative substrate recognition sites (SRSs) of P450 3A4 with the corresponding amino acid of P450 3A5.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top